CSL will collaborate with Inficure in testing their experimental anti-fibrotic reagent in the N-IF mouse.
CSL is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. For over 100 years, CSL has been driven by its promise to save lives using the latest technologies. Today, CSL ‒ including its two businesses, CSL Behring and Seqirus ‒ provides life-saving products to more than 60 countries and employs 22,000 people. The company’s unique combination of commercial strength, R&D focus and operational excellence enables it to identify, develop and deliver innovations so patients can live life to the fullest.
“This collaboration with CSL is tremendously important for us. CSL is the world’s fifth largest biotech company with a long history of successful research and innovation. They have an excellent track record in research commercialisation so this partnership reflects well on the quality and potential of the model we have developed.Prospective partners often ask about who else we are working with. We are very proud to be able to now advise that we are working with one of the world’s leading biotech companies”, Sofia Mayans, CEO Inficure Bio
Inficure now anticipates that future potential partners will better understand the benefits of the model.
International competition from day 1
Inficure has previously carried out tests for an American company from Boston, now they are collaborating with an Australian company. The link between Umeå and Australia originated with a research group at Umeå University.
Text: Elias Eriksson
Photo: Carolina Hawranek
Read more about Inficure Bio
Detailed information about this startup can be found at Inficure Bio’s website – link to webpage.
This news is also covered in;
Local media (Västerbotten-Kuriren Affärsliv 24) in Swedish – link to article.
National branch media (LifeSciencesSweden) in Swedish – link to article.
